Payment overview · 2025
General Payments
$513.02
26 reported records · 11 companies
Healthcare provider profile · identity verified
Patrick P Bunyi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1871518787
Verified facts
What the public records show
CMS Open Payments records show Patrick P Bunyi, M.D. received $513.02 in general payments during 2025 across 26 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Abilify Maintena by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $107.73 | 21.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $105.61 | 20.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.17 | 16.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.35 | 9.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $45.57 | 8.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.60 | 7.1% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.63 | 4.0% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.36 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.18 | 3.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.86 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.96 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.02 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $107.73 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $105.61 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.35 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.01 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $47.20 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $45.57 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 52 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 26 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 745 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 740 | 212 |
| Atorvastatin Calcium | Atorvastatin Calcium | 736 | 228 |
| Losartan Potassium | Losartan Potassium | 639 | 178 |
| Gabapentin | Gabapentin | 489 | 113 |
| Metformin Hcl | Metformin Hcl | 352 | 103 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 322 | 79 |
| Lisinopril | Lisinopril | 313 | 83 |
| Omeprazole | Omeprazole | 283 | 81 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 264 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 71 |
| Alprazolam | Alprazolam | 254 | 30 |
| Furosemide | Furosemide | 241 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 237 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 222 | 72 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 211 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 59 |
| Ibuprofen | Ibuprofen | 200 | 53 |
| Trazodone Hcl | Trazodone Hcl | 196 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 51 |
| Carvedilol | Carvedilol | 191 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 54 |
| Meloxicam | Meloxicam | 184 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 180 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 175 | 47 |
| Lidocaine | Lidocaine | 166 | 41 |
| Lorazepam | Lorazepam | 164 | 21 |
| Clonazepam | Clonazepam | 158 | 24 |
| Diazepam | Diazepam | 156 | 18 |
| Clonidine Hcl | Clonidine Hcl | 154 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 148 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 49 |
| Azithromycin | Azithromycin | 142 | 103 |
| Ondansetron Odt | Ondansetron | 138 | 31 |
| Trulicity | Dulaglutide | 135 | 24 |
| Alendronate Sodium | Alendronate Sodium | 131 | 43 |
| Potassium Chloride | Potassium Chloride | 130 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 26 |
| Simvastatin | Simvastatin | 123 | 40 |
| Ozempic | Semaglutide | 121 | 26 |
| Prednisone | Prednisone | 121 | 74 |
| Mounjaro | Tirzepatide | 120 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 116 | 20 |
| Allopurinol | Allopurinol | 111 | 40 |
| Montelukast Sodium | Montelukast Sodium | 110 | 37 |
| Oxybutynin Chloride | Oxybutynin Chloride | 109 | 15 |
| Sertraline Hcl | Sertraline Hcl | 108 | 27 |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 99 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 20 |
| Tramadol Hcl | Tramadol Hcl | 96 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 25 |
| Baclofen | Baclofen | 82 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 79 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 77 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 16 |
| Donepezil Hcl | Donepezil Hcl | 70 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 22 |
| Celecoxib | Celecoxib | 66 | 16 |
| Haloperidol | Haloperidol | 66 | suppressed |
| Linzess | Linaclotide | 66 | 19 |
| Ketoconazole | Ketoconazole | 65 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 21 |
| Finasteride | Finasteride | 61 | 14 |
| Metformin Hcl Er | Metformin Hcl | 60 | 16 |
| Amoxicillin | Amoxicillin | 59 | 43 |
| Aripiprazole | Aripiprazole | 59 | suppressed |
| Spironolactone | Spironolactone | 59 | 20 |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Estradiol | Estradiol | 57 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 57 | 16 |
| Methocarbamol | Methocarbamol | 55 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | 12 |
| Lactulose | Lactulose | 54 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 14 |
| Temazepam | Temazepam | 53 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 52 | suppressed |
| Eliquis | Apixaban | 52 | 16 |
| Jardiance | Empagliflozin | 52 | 15 |
| Nifedipine Er | Nifedipine | 51 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 25 |
| Meclizine Hcl | Meclizine Hcl | 50 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 17 |
| Nystatin | Nystatin | 47 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | 13 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 30 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 43 | suppressed |
| Atenolol | Atenolol | 42 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 35 |
| Levetiracetam | Levetiracetam | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 13 |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Fenofibrate | Fenofibrate | 35 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Abilify Maintena | Aripiprazole | 33 | suppressed |
| Risperidone Odt | Risperidone | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Famotidine | Famotidine | 32 | 11 |
| Cephalexin | Cephalexin | 31 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 30 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | 11 |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Fluocinonide | Fluocinonide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 16 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Valproic Acid | Valproic Acid | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.02 · 26 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FUROSCIX, JOURNAVX, NURTEC ODT, PREVNAR 20, REXULTI, SUBLOCADE, TRELEGY ELLIPTA, VRAYLAR, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error